Therapeutic Potential of Photobiomodulation for Chronic Kidney Disease

Int J Mol Sci. 2022 Jul 21;23(14):8043. doi: 10.3390/ijms23148043.

Abstract

Chronic kidney disease (CKD) is a growing global public health problem. The implementation of evidence-based clinical practices only defers the development of kidney failure. Death, transplantation, or dialysis are the consequences of kidney failure, resulting in a significant burden on the health system. Hence, innovative therapeutic strategies are urgently needed due to the limitations of current interventions. Photobiomodulation (PBM), a form of non-thermal light therapy, effectively mitigates mitochondrial dysfunction, reactive oxidative stress, inflammation, and gut microbiota dysbiosis, all of which are inherent in CKD. Preliminary studies suggest the benefits of PBM in multiple diseases, including CKD. Hence, this review will provide a concise summary of the underlying action mechanisms of PBM and its potential therapeutic effects on CKD. Based on the findings, PBM may represent a novel, non-invasive and non-pharmacological therapy for CKD, although more studies are necessary before PBM can be widely recommended.

Keywords: chronic kidney disease; gut microbiota dysbiosis; inflammation; mitochondrial dysfunction; oxidative stress; photobiomodulation.

Publication types

  • Review

MeSH terms

  • Dysbiosis
  • Gastrointestinal Microbiome*
  • Humans
  • Inflammation
  • Low-Level Light Therapy*
  • Renal Dialysis
  • Renal Insufficiency, Chronic* / radiotherapy

Grants and funding

This research received no external funding.